Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. SPRY.NASDAQ

Silverback Therapeutics Inc (SPRY NASDAQ) stock market data APIs

$11.25 0.27(2.5%) as of July 26, 2024
Price chart is built with Anychart

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Silverback Therapeutics Inc Financial Data Overview

10.98
11.25
-
11.345
10.93
2.55-11.9
1 084 M
96 895 K
10 000
-0.11
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SPRY',
Type: 'Common Stock',
Name: 'Silverback Therapeutics Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00FZQGXG3',
ISIN: NULL,
CUSIP: NULL,
CIK: '1671858',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-12-04',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Silverback Therapeutics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 10 000
  • EBITDA -61 935 000
  • Earnings Per Share -0.52
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Silverback Therapeutics Inc Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -0.11

Get Silverback Therapeutics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Silverback Therapeutics Inc latest news via APIs

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issuespreviously identified by CHMP, and includes results from a repeat dose...

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024 Resubmission of New Drug Application...
  • ARS PHARMACEUTICALS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • INC
  • NASDAQ:SPRY
Do you have any questions?
support@eodhistoricaldata.com